Combination benefit of a pyrimidylpiperazine derivative (Y-40138) and methotrexate in arthritic rats

European Journal of Pharmacology

Volumn 497, Issue 3, 2004, Pages 351-359

  Hisadome, Masao ^a   Fukuda, Tetsuko ^a   Adachi, Kunitomo ^a   Komatsu, Hirotsugu ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Adjuvant induced arthritis; Combination therapy; Joint destruction; Methotrexate; Y 40138

Indexed keywords

ACETAMIDE DERIVATIVE; METHOTREXATE; N [1 [4 [[4 (PYRIMIDIN 2 YL)PIPERAZIN 1 YL]METHYL]PHENYL]CYCLOPROPYL] ACETAMIDE; PIPERAZINE DERIVATIVE; PYRIMIDYLPIPERAZINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; Y 40138;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; JOINT DESTRUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

EID: 4444335890     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.058     Document Type: Article

References (21)

1. M. Ahern, J. Booth, A. Loxton, P. McCarthy, P. Meffin, and S. Kevat Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal anti-inflammatory drugs? J. Rheumatol. 15 1988 1356 1360
2. A.M. Bendele, J. McComb, T. Gould, J. Frazier, E. Chlipala, J. Seely, G. Kieft, and C.K. Edwards III Effects of PEGylated soluble tumor necrosis factor receptor type I (PEGsTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats Clin. Exp. Rheumatol. 17 1999 553 560
3. P. Chomczynski A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples BioTechniques 15 1993 532 537
4. R. De-Waal-Maleryt, J. Abrams, B. Bennett, C.G. Figdor, and J.E. De-Vries Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes J. Exp. Med. 174 1991 1209 1220
5. M. Feldmann, F.M. Brennan, and R.N. Maini Role of cytokines in rheumatoid arthritis Annu. Rev. Immunol. 14 1996 397 440
6. T. Fukuda, H. Sumichika, M. Murata, T. Hanano, K. Adachi, and M. Hisadome A novel dual regulator of tumor necrosis factor-α and interleukin-10 protects mice from endotoxin-induced shock Eur. J. Pharmacol. 391 2001 317 320
7. J.J.E. Haddad, B. Safieh-Garabedian, N.E. Saade, and S.C. Land The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-κB targeting in the alveolar epithelium Br. J. Pharmacol. 133 2001 49 60
8. P.D. Hall, M.A. Jenner, and M.J. Ahern Hepatotoxicity in a rat model caused by orally administered methotrexate Hepatology 14 1991 906 910
9. M. Hisadome, T. Fukuda, H. Sumichika, T. Hanano, and K. Adachi A novel anti-rheumatic drug suppresses tumor necrosis factor-α and augments interleukin-10 in adjuvant arthritic rats Eur. J. Pharmacol. 409 2001 331 335
10. T. Kuroda, K. Namba, T. Torimaru, K. Kawashima, and M. Hayashi Species differences in oral bioavailability of methotrexate between rats and monkeys Biol. Pharm. Bull. 23 2000 334 338
11. K. Magari, S. Miyata, F. Nishigaki, Y. Ohkubo, S. Mutoh, and T. Goto Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis J. Rheumatol. 30 2003 2193 2200
12. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.M. Woody, T.F. Schaible, and M. Feldmann Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552 1563
13. R.C. Newton, and C.P. Decicco Therapeutic potential and strategies for inhibiting tumor necrosis factor-α J. Med. Chem. 42 1999 2295 2314
14. S. Sakuma, Y. Kato, F. Nishigaki, T. Sasakawa, K. Magari, S. Miyata, Y. Ohkubo, and T. Goto FK506 potently inhibits T cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells Br. J. Pharmacol. 130 2000 1655 1663
15. S. Sakuma, F. Nishigaki, K. Magari, T. Ogawa, S. Miyata, Y. Ohkubo, and T. Goto FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis Inflamm. Res. 50 2001 509 514
16. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, C.G. Jackson, M. Lange, and D.J. Burge A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 1999 253 259
17. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, L.A. Teoh, S.A. Firschkoff, and E.K. Chartash Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial Arthritis Rheum. 48 2003 35 45
18. A.S. Williams, J.P. Camilleri, and B.D. Williams Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat Br. J. Rheumatol. 33 1994 530 533
19. A.S. Williams, J.P. Camilleri, N. Topley, and B.D. Williams Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate J. Pharmacol. Toxicol. Methods 32 1994 53 58
20. A.S. Williams, N. Topley, and B.D. Williams Effect of liposomally encapsulated MTX-DMPE conjugates upon TNFα and PGE2 release by lipopolysaccharide stimulated rat peritoneal macrophages Biochim. Biophys. Acta 1225 1994 217 222
21. R.O. Williams, A.-M. Malfait, D.M. Butler, M.J. Walmsley, M. Feldmann, and R.N. Maini Combination therapy with DMARDs and biological agents in collagen-induced arthritis Clin. Exp. Rheumatol. 17 Suppl. 18 1999 S115 S120